Rheumatoid arthritis: extra-articular manifestations and comorbidities
FA Figus, M Piga, I Azzolin, R McConnell… - Autoimmunity reviews, 2021 - Elsevier
Although synovitis is the pathological hallmark of rheumatoid arthritis (RA), many extra-
articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic …
articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic …
[HTML][HTML] Anticancer drug-induced acute kidney injury
H Izzedine, MA Perazella - Kidney international reports, 2017 - Elsevier
Acute kidney injury (AKI) is a growing problem with untoward economic and medical
consequences. Anticancer drug toxicity remains an important and increasing cause of AKI …
consequences. Anticancer drug toxicity remains an important and increasing cause of AKI …
Codon optimization in the production of recombinant biotherapeutics: potential risks and considerations
VP Mauro - BioDrugs, 2018 - Springer
Biotherapeutics are increasingly becoming the mainstay in the treatment of a variety of
human conditions, particularly in oncology and hematology. The production of therapeutic …
human conditions, particularly in oncology and hematology. The production of therapeutic …
Focus on anti-tumour necrosis factor (TNF)-α-related autoimmune diseases
LR Lopetuso, C Cuomo, I Mignini, A Gasbarrini… - International Journal of …, 2023 - mdpi.com
Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients
affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory …
affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory …
Drug-induced glomerular disease: immune-mediated injury
JJ Hogan, GS Markowitz… - Clinical Journal of the …, 2015 - journals.lww.com
Drug-induced autoimmune disease was initially described decades ago, with reports of
vasculitis and a lupus-like syndrome in patients taking hydralazine, procainamide, and …
vasculitis and a lupus-like syndrome in patients taking hydralazine, procainamide, and …
[HTML][HTML] Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease
Rheumatoid arthritis is associated with reduced kidney function, possibly due to chronic
inflammation or the use of nephrotoxic therapies. However, little is known about the effects of …
inflammation or the use of nephrotoxic therapies. However, little is known about the effects of …
Drug‐induced nephropathies
P Paueksakon, AB Fogo - Histopathology, 2017 - Wiley Online Library
Drugs are associated frequently with the development of various types of acute and chronic
kidney diseases. Nephrotoxicity is associated most commonly with injury in the …
kidney diseases. Nephrotoxicity is associated most commonly with injury in the …
Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study
L Costa, F Caso, R Ramonda, A Del Puente… - Immunologic …, 2015 - Springer
The aim of the study was to evaluate the influence of metabolic syndrome (MetS) on
achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients treated with anti …
achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients treated with anti …
[HTML][HTML] Paradoxical reactions to biologicals in chronic inflammatory systemic diseases
I Kremenevski, O Sander, M Sticherling… - Deutsches Ärzteblatt …, 2022 - ncbi.nlm.nih.gov
Background Biological agents that contain substances affecting the immune system are
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …
Chimeric fusion proteins used for therapy: indications, mechanisms, and safety
BA Baldo - Drug safety, 2015 - Springer
Chimeric fusion proteins, produced by genetic engineering, are currently made up of effector
peptides, for example, a ligand-binding portion of a cytokine or growth factor, extracellular …
peptides, for example, a ligand-binding portion of a cytokine or growth factor, extracellular …